Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.

Minran Zhou,Jiping Zeng,Xiaoming Wang,Xiangyu Wang,Tao Huang,Yue Fu,Ting Sun,Jihui Jia,Chunyan Chen
DOI: https://doi.org/10.18632/oncotarget.2859
2015-01-01
Oncotarget
Abstract:Chronic myeloid leukemia in the blastic phase (CML-BP) responds poorly to clinical treatments and is usually fatal. In this study, we found that the histone H3 lysine 4 (H3K4) demethylase RBP2 (also called JARID1A and KDM5A) is underexpressed in CML-BP. The RBP2 histone demethylase stimulates leukemia cell differentiation and inhibits cell proliferation. We identified miR-21 was directly downregulated by RBP2 and found that miR-21 downregulated PDCD4 expression in leukemia cells. By binding to miR-21 promoter and by demethylating of trimethylated H3K4 at the miR-21 locus, RBP2 downregulated miR-21 expression. This in turn activated PDCD4. In conclusion, RBP2 epigenetically downregulated miR-21 in blast transformation of CML.
What problem does this paper attempt to address?